Wockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of net losses. The drug, targeting multidrug-resistant bacteria, has a projected peak sales of $1.5 billion, potentially transforming the company's financial outlook. Investors have responded positively, with the stock surging on the news.
from Economic Times https://ift.tt/6BzYHPZ
Subscribe to:
Post Comments (Atom)
-
The value had touched a high of 22% of total market capitalisation of listed firms in June 2009, dropping to a low of 5.1% in September 2020...
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
No comments:
Post a Comment